erythromycin lactobionate: clinical use

Prescribing considerations

• Confirm that the organism and infection are appropriate for erythromycin, considering local susceptibility and antimicrobial policy.
• Review cardiac disease, bradycardia, QT-prolonging medicines and factors causing low potassium or magnesium.
• Use caution in hepatic or significant renal impairment and in older people.
• Erythromycin can exacerbate myasthenia gravis, including respiratory weakness.
• In young infants, balance the indication against the risk of infantile hypertrophic pyloric stenosis.

Contraindications and cautions

• Hypersensitivity to erythromycin, formulation components or another macrolide
• Severe hepatic impairment or severe decompensated heart failure
• Congenital or documented acquired QT prolongation, previous ventricular arrhythmia or torsades de pointes
• Hypokalaemia or hypomagnesaemia
• Concomitant medicines specifically contraindicated by the product information, including certain QT-prolonging medicines, ergot alkaloids, simvastatin, atorvastatin, lovastatin and lomitapide
• Intravenous bolus, intramuscular or intra-arterial administration

Monitoring

• Review cardiac risk and consider ECG assessment where clinically indicated.
• Check and correct potassium and magnesium when risk factors are present.
• Monitor hepatic function where clinically appropriate.
• Assess renal function and watch for hearing disturbance in higher-risk patients.
• Monitor for infusion-site irritation, severe diarrhoea, hypersensitivity and superinfection.
• Use medicine-specific monitoring for continued interacting treatments.

Clinical pharmacology

A macrolide antibacterial that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It distributes widely into tissues, undergoes hepatic handling with biliary excretion, and inhibits CYP3A4 and P-glycoprotein.

Formulation and product differences

• A hygroscopic powder containing erythromycin as erythromycin lactobionate, with no listed excipients.
• Requires separate reconstitution and dilution before intravenous infusion.
• Preparation fluids and infusion mixtures must follow current product instructions; do not mix indiscriminately with other medicines.

Solution for infusion

Route: Intravenous

Strengths: 1 g